Adverse events after colonoscopy in a randomised colorectal cancer screening trial.


Journal

BMJ open gastroenterology
ISSN: 2054-4774
Titre abrégé: BMJ Open Gastroenterol
Pays: England
ID NLM: 101660690

Informations de publication

Date de publication:
07 Oct 2024
Historique:
received: 23 05 2024
accepted: 19 09 2024
medline: 8 10 2024
pubmed: 8 10 2024
entrez: 7 10 2024
Statut: epublish

Résumé

Colonoscopy-related adverse events increase the burden of colorectal cancer (CRC) screening. This cross-sectional study evaluates adverse events during and after colonoscopy in a large, randomised CRC screening trial in Norway comparing sigmoidoscopy to immunochemical testing for faecal blood. We included all individuals who underwent colonoscopy at two screening centres between 2012 and 2020. From medical records, we retrieved data on adverse events during and within 30 days after colonoscopy and classified them according to the American Society for Gastrointestinal Endoscopy lexicon for endoscopic adverse events. Multivariable logistic regression models were fitted to identify risk factors for adverse events. Of the 10 244 included individuals, 242 (2.4%) had at least one adverse event that was possibly, probably, or definitively related to the colonoscopy. 188 (1.8%) had mild adverse events, 50 (0.49%) had moderate, 3 (0.03%) had severe, and 1 had a fatal adverse event. The most frequent adverse events were lower gastrointestinal bleeding (0.86%), abdominal pain (0.48%), vasovagal reaction (0.39%), postpolypectomy syndrome (0.20%), and perforation (0.08%). 23 (0.22%) individuals had non-gastrointestinal adverse events. Risk factors associated with adverse events were older age, female sex, screening centre, anticoagulant therapy, number of polypectomies, size of lesion removed, presence of proximal lesion, and adenocarcinoma. Adverse event rates per endoscopist ranged from 0% to 4.9%. Adverse events after colonoscopy of screening positives occurred in about 2 out of 100 procedures. Three-quarters of events were mild. Awareness of risk factors may help endoscopists to mitigate the risk. NCT01538550.

Identifiants

pubmed: 39375173
pii: bmjgast-2024-001471
doi: 10.1136/bmjgast-2024-001471
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT01538550']

Types de publication

Journal Article Randomized Controlled Trial Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: The bowel preparation used for colonoscopy was provided free of charge by Ferring Pharmaceuticals. SOF reports Chairman, The Norwegian Society of Clinical Nutrition and Metabolism; Council Member, European Society for Clinical Nutrition and Metabolism outside of the submitted work.

Auteurs

Øyvind Bakken Rognstad (ØB)

Cancer Registry of Norway, Section for Colorectal Cancer Screening, Norwegian Institute of Public Health, Oslo, Norway.
Clinical Effectiveness Research Group, Institute of Health and Society, University of Oslo, Oslo, Norway.
Clinical Effectiveness Research Group, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
Department of Medicine, Sykehuset Innlandet HF, Innlandet Hospital Trust, Lillehammer, Norway.

Edoardo Botteri (E)

Cancer Registry of Norway, Section for Colorectal Cancer Screening, Norwegian Institute of Public Health, Oslo, Norway.
Cancer Registry of Norway, Department of Research, Norwegian Institute of Public Health, Oslo, Norway.

Geir Hoff (G)

Cancer Registry of Norway, Section for Colorectal Cancer Screening, Norwegian Institute of Public Health, Oslo, Norway.
Department of Research and Development, Telemark Hospital, Skien, Norway.

Michael Bretthauer (M)

Clinical Effectiveness Research Group, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Elisabeth Gulichsen (E)

Department of Medicine, Sykehuset Østfold HF, Moss, Norway.

Svein Oskar Frigstad (SO)

Department of Medicine, Vestre Viken Hospital Trust, Bærum, Norway.

Øyvind Holme (Ø)

Clinical Effectiveness Research Group, Institute of Health and Society, University of Oslo, Oslo, Norway.
Department of Research, Sørlandet Sykehus HF, Kristiansand, Norway.

Kristin Ranheim Randel (KR)

Cancer Registry of Norway, Section for Colorectal Cancer Screening, Norwegian Institute of Public Health, Oslo, Norway kran@kreftregisteret.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH